Riegel v. Medtronic, Inc.

2008-02-20

Headline: Ruling blocks state tort lawsuits challenging safety of FDA premarket-approved high-risk medical devices, making it harder for injured patients to recover under state law while federal approval remains in force.

Holding: The Court held that federal medical-device law prevents state tort claims that challenge the safety or effectiveness of a medical device once the FDA has given it premarket approval.

Real World Impact:

Makes it harder for injured patients to win state tort suits against FDA-approved high-risk devices.
Gives manufacturers greater protection from jury awards that would require changes to approved designs or labels.
Leaves open some claims that directly allege violation of FDA rules or run in parallel.

Topics: medical devices, FDA approval, product liability, state consumer lawsuits

Summary

Background

A patient and his wife sued a medical device maker after a coronary catheter ruptured during heart surgery, causing serious injury. The catheter is a high-risk (Class III) product that received FDA premarket approval. The couple sued under New York common law, alleging defective design, labeling, and manufacture. Lower courts dismissed those state claims as preempted under federal medical-device law, and the Second Circuit affirmed.

Reasoning

The central question was whether the Medical Device Amendments’ pre-emption clause prevents state common-law claims that challenge the safety or effectiveness of a device that won FDA premarket approval. The Court said yes: the premarket approval process creates device-specific federal requirements and state tort duties count as requirements. If a state claim would impose requirements different from or in addition to the federal ones and it concerns safety or effectiveness, the claim is barred. The Court declined to decide whether claims that run in parallel with federal requirements survive.

Real world impact

The decision limits many state-law lawsuits seeking money for injuries tied to FDA-approved high-risk devices, making it harder for patients to recover through state tort claims. Manufacturers gain stronger protection from jury verdicts that would require changes to approved designs or labels. Some claims may still proceed if they are based on violations of FDA rules or clearly parallel federal requirements, but the Court left that question for another day.

Dissents or concurrances

One Justice joined most of the Court’s opinion but wrote separately about statutory history. A dissent argued Congress did not intend to cut off state damage suits and warned the ruling removes an important layer of consumer protection.